Ademetionine(b)

Research use only, not for human use.

Ademetionine is an intermediate metabolite of methioninefor treatment of primary biliary cirrhosis and major depressive disorder.

Ademetionine is an intermediate metabolite of methioninefor treatment of primary biliary cirrhosis and major depressive disorder.

Apoptosis Analysis Cell Line:Cal-33 and JHU-SCC-011 cells Concentration:300 μM Incubation Time:24 h (Cal-33) or 48 h (HU-SCC-011)Result:Showed an approximately 10% and 3%of apoptotic cells respectively.Cell Cycle Analysis Cell Line:Cal-33 and JHU-SCC-011 cells Concentration:300 μM Incubation Time:24 h (Cal-33) or 48 h (HU-SCC-011)Result:Decreased the expression of cyclin B1, E1 and D1 in the Cal-33 and JHU-SCC-011 cells.

Animal Model:Valproic acid treated young mice Dosage:30?mg/kg Administration:p.o., for 3 days Result:Alleviated most ASD like neurobehavioral symptoms.Normalized the redox potential in the prefrontal cortex.

S-Adenosyl-L-methionine | S-Adenosyl methionine | SAMe | AdoMet

Others

Other Targets

Others

Neurological Disease

Major depressive disorder

29908-03-0

398.44

C15H22N6O5S

>98% (HPLC)

DMSO:100 mg/mL (250.98 mM);H2O:43 mg/mL (107.92 mM)

C[S+](CCC(N)C(=O)[O-])CC1OC(n2cnc3c(N)ncnc32)C(O)C1O

(2S)-2-amino-4-((((2S3S4R5R)-5-(6-amino-9H-purin-9-yl)-34-dihydroxytetrahydrofuran-2-yl)methyl)(methyl)sulfonio)butanoate

(-20℃)

With Ice Pack

≥ 2 years